Coherus Oncology (FRA:8C5) Interest Expense: €-7.77 Mil (TTM As of Mar. 2026)

What is Coherus Oncology Interest Expense?

Coherus Oncology FRA:8C5 -2.10% 49 Interest Expense is €-7.77 Mil as of Mar. 2026. GuruFocus rates FRA:8C5 with a GF Score™ of 49/100 and a GF Value™ of €0.64 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Coherus Oncology's interest expense for the three months ended in Mar. 2026 was € -1.89 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-7.77 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Coherus Oncology's Operating Income for the three months ended in Mar. 2026 was € -31.27 Mil. Coherus Oncology's Interest Expense for the three months ended in Mar. 2026 was € -1.89 Mil. Coherus Oncology did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Coherus Oncology (FRA:8C5) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Coherus Oncology's Interest Expense for the three months ended in Mar. 2026 was €-1.89 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-31.27 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €32.96 Mil.

Coherus Oncology's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Coherus Oncology did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Coherus Oncology Interest Expense Historical Data

* Premium members only.

The historical data trend for Coherus Oncology's Interest Expense can be seen below:

Coherus Oncology Interest Expense Chart

Coherus Oncology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-20.32

-30.66

-37.18

-10.25

-7.69

Coherus Oncology Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-1.99	-1.97	-1.98	-1.92	-1.89

49GF Score

Coherus Oncology Inc FRA:8C5

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Coherus Oncology Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.77 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of €-7.77 Mil mean?

Coherus Oncology (FRA:8C5) has a Interest Expense of €-7.77 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Coherus Oncology and its competitors.

Is Coherus Oncology's Interest Expense too high?

Coherus Oncology's current Interest Expense is €-7.77 Mil. Overall, Coherus Oncology has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Coherus Oncology's Interest Expense compare to TARA and KPTI?

Coherus Oncology's Interest Expense of €-7.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current Interest Expense is €-7.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Coherus Oncology stock overvalued right now?

Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.64, compared to a current price of €1.40 — trading 118.6% above its estimated fair value. The current Interest Expense is €-7.77 Mil. Coherus Oncology's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Interest Expense is €-7.77 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coherus Oncology (FRA:8C5) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of €1.40 is trading 118.6% above its estimated GF Value™ of €0.64. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for FRA:8C5:

Interest Expense: €-7.77 Mil
GF Value™: €0.64 vs. price of €1.40 (118.6% above fair value)
GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Industry Healthcare Biotechnology

Comparable Companies TARA KPTI CNTN RNA QTTB AVXL SLGL CAMP CDXS KROS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges CHRS:USA

Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website https://www.coherus.com

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

49GF Score

Get the complete analysis for FRA:8C5

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.40

Price

€0.64

GF Value

View FRA:8C5 Analysis

See Interest Expense data for all stocks →